Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease

NCT00985517 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT00985517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00985517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Lead sponsor
Sangamo Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
October 29, 2009
Completion date
November 16, 2017
Enrollment
57 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease